Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET
Company Participants
Eric Sciorilli - Head of Investor Relations
Terrie Curran - President & Chief Executive Officer
Martin Gilligan - Chief Commercial Officer
Molly Henderson - Chief Financial & Business Officer
Azmi Nabulsi - Chief Operating Officer
Conference Call Participants
Annabel Samimy - Stifel
Paul Choi - Goldman Sachs
Joseph Stringer - Needham & Company
Yatin Suneja - Guggenheim
Chase Knickerbocker - Craig-Hallum
Matthew Caufield - H.C. Wainwright
Operator
Hello, and welcome to the Phathom Pharmaceuticals Third Quarter 2024 Earnings Results Call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised that today's call is being recorded.
With that, I would like to turn the conference over to Eric Sciorilli, Phathom's Head of Investor Relations. Please go ahead.
Eric Sciorilli
Thank you, operator. Hello, everyone, and thank you for joining us this morning to discuss Phathom's third quarter 2024 results. This morning's presentation will include remarks from Terrie Curran, our President and CEO; Martin Gilligan, our Chief Commercial Officer; and Molly Henderson, our Chief Financial Officer. Azmi Nabulsi, our Chief Operating Officer will also be joining the team during the Q&A portion of today's call.
Just a couple of logistical items before we get started. Earlier this morning, we issued a press release detailing the results we will be discussing during the call. A copy of that press release can be found under the News Releases section of our corporate website. Further, the recording of today's webcast can be found under the Events and Presentations section of our corporate website.
Before we begin, let me remind you that we will be making a number of forward-looking statements throughout today's presentation. These forward-looking statements involve risks and uncertainties, many of which are beyond Phathom's control. Actual results can materially differ from the forward-looking statements, and any such risks can materially adversely affect the business, the results of operations and trading prices for Phathom's common stock.
A discussion of these statements and risk factors is available on the current Safe Harbor slide as well as in the Risk Factors section of our most recent Form 10-K and subsequent SEC filings. All forward-looking statements made on this call are based on the beliefs of Phathom as of this date, and Phathom disclaims any obligation to update these statements.